Vimarsana
Biggest News Aggregation in the World

Nasdaq Nrix News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq Nrix. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Nrix Today - Breaking & Trending Today

Nurix Therapeutics Announces Pricing of Upsized $175.0 - Vimarsana News

Nurix Therapeutics Announces Pricing of Upsized $175.0

SAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the pricing of its upsized underwritten public...

Wells Fargo & Company Cuts Nurix Therapeutics (NASDAQ:NRIX) Price Target to $20.00 - Vimarsana News

Wells Fargo & Company Cuts Nurix Therapeutics (NASDAQ:NRIX) Price Target to $20.00

Nurix Therapeutics (NASDAQ:NRIX – Free Report) had its price target lowered by Wells Fargo & Company from $23.00 to $20.00 in a research note published on Friday, Benzinga reports. Wells Fargo & Company currently has an overweight rating on the stock. A number of other research firms also recently weighed in on NRIX. Needham & […]

Source: wkrb13.com
Nurix Therapeutics Announces Publication in the Journal - Vimarsana News

Nurix Therapeutics Announces Publication in the Journal

Data reveal oncogenic scaffold function of BTK mutations that lack kinase activity and show these mutations remain susceptible to degradation by NX-2127 ...

Analysts Set Nurix Therapeutics, Inc. (NASDAQ:NRIX) Price Target at $28.86 - Vimarsana News

Analysts Set Nurix Therapeutics, Inc. (NASDAQ:NRIX) Price Target at $28.86

Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) have earned a consensus recommendation of “Buy” from the seven ratings firms that are currently covering the firm, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have issued a report on […]

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives $28.86 Consensus Target Price from Brokerages - Vimarsana News

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives $28.86 Consensus Target Price from Brokerages

Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) has been assigned an average recommendation of “Buy” from the seven brokerages that are currently covering the stock, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average 1-year price objective among brokerages that have updated their coverage on the […]